News and Announcements
Significant Advance in Development of Actinogen’s Alzheimer’s Drug
- Published December 19, 2016 1:09PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
19th December 2016 – ASX Announcement
- Xanamem™ human research data accepted for publication in major medical journal
- Xanamem™ specifically designed to inhibit excess cortisol production in the brain
- Excess cortisol in the brain associated with Alzheimer’s disease
- Xanamem™ being trialled in Alzheimer’s disease to confirm earlier treatment success
In significant advance in the development of Xanamem™, Actinogen Medical Ltd (ASX: ACW) in pleased to announce that their human research data on Xanamem™ has been accepted for publication in the prestigious pee-reviewed medical journal – the British Journal of Pharmacology. The paper: Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteriod dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™) will be available online early in the new year.
To view the full announcement please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
